Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: 1300 128 339

Office Hours:
Wednesdays, 10am-3pm


FIBROMYALGIA HELP:
Contact
Fibromyalgia SA
at the
Arthritis Foundation of SA
118 Richmond Road,
Marleston 5033
Ph: (08) 8379 5711

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form 2014 (PDF, 290KB)
Why become a member?

University of Utah recruiting for pregabalin biomarker study

Friday 20 July 2012

 

From ProHealth:

 

LyricaU of Utah Recruiting Fibromyalgia & FM/CFS Patients for Pregabalin Biomarker Study

ProHealth.com • July 12, 2012

Why does Lyrica® (generic name pregabalin) help some FM patients and not others?

The Department of Anesthesiology at the University of Utah, Salt Lake City, announced July 10 that it is seeking participants for a study to investigate Lyrica’s “effects on blood biomarkers” in patients with fibromyalgia or FM & chronic fatigue syndrome (ME/CFS).

Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA approval in 2007* for treatment of fibromyalgia.

Study Details

According to the July 10 blood biomarkers study announcement:

  • Researchers hope to learn more about why Lyrica is effective for some patients and not for others.

  • Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who are not currently using Lyrica are needed to participate in this IRB-approved trial.
     
  • Eligible volunteers will receive Lyrica for five weeks and a placebo for five weeks, and will be compensated for their time.
     
  • For more information, contact Andrea White (andrea.white@hsc.utah.edu)

___

* As Pfizer's Lyrica patents begin expiring, in October 2013, the $3.4 billion annual Lyrica market will be opening to ‘generic’ (generally lower price) versions of the drug, and as of July 5, the FDA approved marketing of a generic pregabalin product by Lupin Pharmaceuticals.

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page